AU2022211609A1 - Naltrexone compositions - Google Patents

Naltrexone compositions Download PDF

Info

Publication number
AU2022211609A1
AU2022211609A1 AU2022211609A AU2022211609A AU2022211609A1 AU 2022211609 A1 AU2022211609 A1 AU 2022211609A1 AU 2022211609 A AU2022211609 A AU 2022211609A AU 2022211609 A AU2022211609 A AU 2022211609A AU 2022211609 A1 AU2022211609 A1 AU 2022211609A1
Authority
AU
Australia
Prior art keywords
single unit
pharmaceutical composition
formulation
dose pharmaceutical
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022211609A
Other languages
English (en)
Other versions
AU2022211609A9 (en
Inventor
Francis HOOD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LDN Pharma Ltd
Original Assignee
LDN Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LDN Pharma Ltd filed Critical LDN Pharma Ltd
Publication of AU2022211609A1 publication Critical patent/AU2022211609A1/en
Publication of AU2022211609A9 publication Critical patent/AU2022211609A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022211609A 2021-01-25 2022-01-25 Naltrexone compositions Pending AU2022211609A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21153332 2021-01-25
EP21153332.8 2021-01-25
PCT/EP2022/051619 WO2022157385A1 (en) 2021-01-25 2022-01-25 Naltrexone compositions

Publications (2)

Publication Number Publication Date
AU2022211609A1 true AU2022211609A1 (en) 2023-07-27
AU2022211609A9 AU2022211609A9 (en) 2025-03-13

Family

ID=74236099

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022211609A Pending AU2022211609A1 (en) 2021-01-25 2022-01-25 Naltrexone compositions

Country Status (9)

Country Link
US (1) US20240108583A1 (https=)
EP (1) EP4281046B1 (https=)
JP (1) JP2024505018A (https=)
KR (1) KR20230136180A (https=)
CN (1) CN117545472A (https=)
AU (1) AU2022211609A1 (https=)
CA (1) CA3207647A1 (https=)
IL (1) IL304652A (https=)
WO (1) WO2022157385A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022103638A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
GB202109018D0 (en) * 2021-06-23 2021-08-04 Ldn Pharma Ltd Treatment with an agonist of a 5-hydroxytryptamine (5-ht) receptor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
GB0513984D0 (en) * 2005-07-07 2005-08-17 Teva Pharma Dosage form
EP1980245A1 (en) * 2007-04-11 2008-10-15 Cephalon France Bilayer lyophilized pharmaceutical compositions and methods of making and using same
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
US9205081B2 (en) * 2010-04-29 2015-12-08 Allodynic Therapeutics, Llc Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
US20140371210A1 (en) * 2011-10-13 2014-12-18 Jaleva Pharmaceuticals, Llc Methods and compositions for rapid transbuccal delivery of active agents
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
BR112017018316A2 (pt) * 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases
JP6968184B2 (ja) * 2016-10-25 2021-11-17 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 速崩壊多層錠のための異なる密度の組成物
US10517834B2 (en) * 2017-05-16 2019-12-31 Owen Murray Fast dissolving tablet formulations and methods of making thereof
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
GB201805207D0 (en) * 2018-03-29 2018-05-16 Ldn Pharma Ltd Autoimmune therapy
CN109316454B (zh) * 2018-11-26 2021-06-15 正大制药（青岛）有限公司 一种骨化三醇制剂
EP3934647A1 (en) * 2019-03-06 2022-01-12 LDN Pharma Limited Method for determining efficacy
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
US12453750B2 (en) * 2019-03-21 2025-10-28 Alvit Lcs Pharma Ltd. Fixed dose combination of cannabinoids and medical mushrooms for prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases

Also Published As

Publication number Publication date
CA3207647A1 (en) 2022-07-28
EP4281046B1 (en) 2025-09-10
JP2024505018A (ja) 2024-02-02
KR20230136180A (ko) 2023-09-26
IL304652A (en) 2023-09-01
WO2022157385A1 (en) 2022-07-28
EP4281046A1 (en) 2023-11-29
AU2022211609A9 (en) 2025-03-13
US20240108583A1 (en) 2024-04-04
CN117545472A (zh) 2024-02-09
EP4281046C0 (en) 2025-09-10

Similar Documents

Publication Publication Date Title
AU2019306787B2 (en) Extended release formulations of cannabinoids
RU2485949C2 (ru) Таблетка мелатонина и способы изготовления и применения
AU2015292915B2 (en) Solid dosage form composition for buccal or sublingual administration of cannabinoids
RU2487703C2 (ru) Фармацевтические композиции, включающие модулятор s1р
ES2292614T3 (es) Formulacion oral de fusion rapida de un inhibidor de ciclooxigenasa-2.
JP2004506680A (ja) シクロオキシゲナーゼ−２阻害剤の迅速崩壊経口製剤
US20070184109A1 (en) Compositions comprising triptans and nsaids
TW201247240A (en) Rapid dissolve tablet compositions for vaginal administration
KR20060019639A (ko) 발데콕시브 조성물
US20240108583A1 (en) Naltrexone compositions
JP2005519061A (ja) パピローマウイルス感染症を治療するための、ｃｏｘ−２阻害剤と抗ウイルス剤との組み合わせ使用
US20250281481A1 (en) Naltrexone for boosting the therapeutic utilty of 5-ht receptor agonists
TWI673069B (zh) 超高速崩解錠劑及其製造方法
AU2004287257A1 (en) Oral formulations for 5-HT-receptor agonists, uses and methods of treatment employing the same
RU2369396C2 (ru) Фармацевтическая композиция, содержащая оксоплатин, его соли и производные
TW200423929A (en) Pharmaceutical combination
CN104434948A (zh) 一种抗胰腺癌的药物组合物及其应用
MD3439637T2 (ro) Procedeu pentru formulări solide de mesalazină
RU2424809C1 (ru) Противотуберкулезное лекарственное средство
WO2025068971A1 (en) Compositions containing cabazitaxel and lipids for oral administration
CN104434947B (zh) 一种抗胆管癌的药物组合物及其应用
ZA200509860B (en) Composition comprising triptans and NSAIDS
MXPA01008055A (en) Valdecoxib compositions
PL1462149T3 (pl) Zastosowanie fenazonu do leczenia migreny
MXPA05013201A (en) Composition comprising triptans and nsaids

Legal Events

Date Code Title Description
SREP Specification republished